Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia
The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S64315 with azacitidine in patients with acute myeloid leukaemia.
Acute Myeloid Leukaemia
DRUG: S 64315 (also referred as MIK665) and azacitidine
Dose Limiting Toxicity (DLT) (Phase I - Dose Escalation), Incidence of DLTs starting from the Lead-In Dose period to the end of the first cycle of treatment of S64315 in combination with azacitidine., Day -13 to Cycle 1 Day 28 (each cycle is 28 days)|Number of Adverse Events (AEs) and Severe AEs (Phase I - Dose Escalation), Incidence and severity of AEs according to NCI CTCAE v5.0, an average of 6 months|Number of Serious Adverse Event (SAEs) and Fatal SAEs (Phase I - Dose Escalation), Incidence and severity of SAEs according to NCI CTCAE v5.0, Day -13 up to 30 calendar days after the patient's last study visit (an average of 6 months)|Number of Participants With Dose Interruptions (Phase I - Dose Escalation), Through study completion, an average of 6 months|Number of Participants With Dose Reductions (Phase I - Dose Escalation), Through study completion, an average of 6 months|Dose Intensity for S64315 (Phase I - Dose Escalation), Through study completion, an average of 6 months|Dose Intensity for Azacitidine (Phase I - Dose Escalation), Through study completion, an average of 6 months
Assess Anti-leukemic Activity of S64315 in Combination With Azacitidine (Phase I - Dose Escalation), Overall survival (OS), Through study completion, an average of 6 months|Assess Anti-leukemic Activity of S64315 in Combinaison With Azacitidine (Phase I - Dose Escalation), Duration of response (DOR), Through study completion, an average of 6 months|Assess Anti-leukemic Activity of S64315 in Combinaison With Azacitidine (Phase I - Dose Escalation), Best overall response (BOR), Through study completion, an average of 6 months|Assess Anti-leukemic Activity of S64315 in Combinaison With Azacitidine (Phase I - Dose Escalation), Progression-free survival (PFS), Through study completion, an average of 6 months|Assess Anti-leukemic Activity of S64315 in Combinaison With Azacitidine (Phase I - Dose Escalation), Disease-free survival (DFS), Through study completion, an average of 6 months|Pharmacokinetic Profile of S64315 Administered in Combination With Azacitidine in Plasma: Area Under the Curve (AUC) (Phase I - Dose Escalation), At Cycle 1 Day 2 and Cycle 1 Day 9 (each cycle is 28 days)|Pharmacokinetic Profile of S64315 Administered in Combination With Azacitidine in Plasma: Maximum Concentration (Cmax) (Phase I - Dose Escalation), At Cycle 1 Day 2 and Cycle 1 Day 9 (each cycle is 28 days)
The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S64315 with azacitidine in patients with acute myeloid leukaemia.